Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft Model

Fig. 3

Comparison of histologic changes after treatment with 200 µg/kg/day of IL-13 cytotoxin by IV or CI. Male mice bearing HN12 subcutaneous tumors were treated with 200 µg/kg/day of IL13-PE38QQR by either IV or CI from day 4 to day 10 (7 days). On day 11, organs were harvested for histologic examination.

Back to article page